Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China

References

• Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 2006;50:1257-62
   PubMed Web of Science ®Google Scholar
• Pfaller M, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clin Infect Dis 2006;42(Suppl. 4):S153-63
   PubMed Web of Science ®Google Scholar
• Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:S164-72
   PubMed Web of Science ®Google Scholar
• Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004). Diagn Microbiol Infect Dis 2005;53:257-64
   PubMed Web of Science ®Google Scholar
• Kaye K, Engemann J, Fraimow H, et al. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms and clinical management. Infect Dis Clin North Am 2004;18:467-511
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. M100S15. Wayne, PA, USA: Clinical and Laboratory Standards Institute, 2005
   Google Scholar
• Bush K. New beta-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-9
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991;35:1697-704
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;6:1433-7
   Google Scholar
• Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring. Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-73
   Google Scholar
• Hsueh PR, Snyder TA, Dinubile MJ, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2006;28:238-43
   Google Scholar
• Chow J, Satishchandran V, Snyder T, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2005;6:439-48
   Google Scholar
• Baquero F, Hsueh PR, Paterson DL, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2009;10:99-104
   Google Scholar
• Bradford P. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51
   PubMed Web of Science ®Google Scholar
• Wiener J, Quinn JP, Bradford P, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:563-4
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Kiratisin P, Saifon P, et al. Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: a case–case–control study. Am J Infect Control 2007;35:606-12
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Alcala J, Cisnerosn J, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-902
   PubMed Web of Science ®Google Scholar
• Tian SF, Chen BY, Chu YZ, et al. Prevalence of rectal carriage of extended-spectrum β-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008;54:781-5
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Schwaber M, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006;42:925-34
   PubMed Web of Science ®Google Scholar
• Moor C, Roberts S, Simmons G, et al. Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect 2008;68:355-62
   PubMed Web of Science ®Google Scholar
• Pitout J, Nordmann P, Laupland K, et al. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-9
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu D, Hu F. Changes of antimicrobial resistance among clinical isolates of Escherichia coli in Shanghai 1990–2000. Natl Med J China 2006;86:12-6
   Google Scholar
• Wang F, on behalf of CHINET Working Group. CHINET 2006 surveillance of bacterial resistance in China. Chin J Infect Chemother 2008;8:1-9
   Google Scholar
• Wang H, Chen M, Ni Y, et al. Antimicrobial resistance analysis among nosocomial Gram-negative bacilli from 10 teaching hospitals in China in 2006. Chin J Lab Med 2008;31:623-7
   Google Scholar
• Yang QW, Xu YC, Chen MJ, et al. Surveillance of antimicrobial resistance among nosocomial Gram-negative pathogens from 15 teaching hospitals in China in 2005. Natl Med J China 2007;87:2753-8
   Google Scholar
• Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumonia. Infect Control Hosp Epidemiol 2004;25:860-7
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, et al. Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia. Korean J Intern Med 2004;19:160-4
   PubMedGoogle Scholar
• Lee SY, Kotapati S, Kuti JL, et al. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006;27:1226-32
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71
   PubMed Web of Science ®Google Scholar
• Moland ES, Black JA, Ourada J, et al. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother 2002;46:3837-42
   PubMed Web of Science ®Google Scholar
• Lee SY, Kuti, JL, Nicolau DPl. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect 2007;54:463-8
   PubMed Web of Science ®Google Scholar
• Ko WC, Hsueh PR. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002–2006. J Infect 2009;59:95-103
   PubMed Web of Science ®Google Scholar
• Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009;53:3280-4
   PubMed Web of Science ®Google Scholar